XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, announced that it has signed an agreement with Applied Pharmaceutical Innovation. A not-for-profit institution at the University of Alberta, Applied supports translational drug development for industry and innovators. XPhyto’s psychedelic pharmaceutical production agreement calls for the synthesis … Continue reading “NetworkNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Signs Production Agreement with Applied Pharmaceutical Innovation”
XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities The company has research and development operations in North America and Europe and an operational focus in Germany XPhyto’s operations are concentrated into three core divisions: infectious disease diagnostics, clinical development of transdermal and sublingual … Continue reading “XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Is ‘One to Watch’”
Investment Considerations BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. The company has research and development operations in North America and Europe and an operational focus in Germany. BioNxt’s operations are concentrated into three core divisions: infectious disease diagnostics, clinical development of transdermal … Continue reading “BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF) (FSE: 4XT)”
Champignon Brands (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF), a research-driven company specializing in breakthrough ketamine treatment for depression and other mental health conditions, has opened its third Canadian Rapid Treatment Center of Excellence (“CRTCE”) clinic. Champignon chairman and CEO Roger McIntyre announced the opening of the center; the announcement noted that the clinics — the … Continue reading “NetworkNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) Opens New CRTCE Clinic to Provide Ketamine Treatment for Adults with Depression”
Pure Extracts (CSE: PULL), a plant-based extraction company, is focused on cannabis, hemp, and functional mushroom sectors, the last of which is projected to rise to a value of $34.4 billion by the end of 2024. Seeking to capitalize on the growing interest within the sector, Pure Extracts has expanded its business model to include … Continue reading “NetworkNewsBreaks – Pure Extracts Technologies Corp. (CSE: PULL) Leverages Key Experience, Prepares Entry into Psychedelic Mushroom Market”
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) chairman and CEO Roger McIntyre today announced the company’s appointment of Stephen R. Brooks as its new chief financial officer and Peter Rizakos as the firm’s new general counsel. According to the update, these appointments complete the company’s new top management team put into place by Dr. McIntyre … Continue reading “NetworkNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces New CFO, General Counsel”
Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) today announced the publication of an article led by Dr. Roger McIntyre, CEO of Champignon Brands Inc. The article, “Bipolar Disorders” is published in The Lancet – one of the world’s best-known and most reputable scientific journals in medicine. According to the update, the article contributes to The … Continue reading “NetworkNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Announces Article Outlining Future Potential in Novel Agents for Bipolar Disorders”
Pure Extracts Technologies Corp. has announced plans to expand, build fourth unit in dedicated towards research, development of psilocybin Announcement on its expansion plans come shortly after the Company revealed it plans to apply to Health Canada for a Dealer’s License Award of Dealer’s License would allow Pure Extracts to cultivate, harvest and procure controlled … Continue reading “Pure Extracts Technologies (CSE: PULL) Draws Out Expansion Plans in Anticipation of Regulatory Changes Within Mushroom Sector”
Pure Extracts Technologies revealed it had recently retained global consultancy to advise on application for Dealer’s License under Health Canada If granted, license would allow Company to cultivate, conduct research into, commercialize controlled substances Pure Extracts also announced it recently signed LOI to further cooperation with PURICA(TM)( in field of full-spectrum mushroom-derived wellness products and … Continue reading “Pure Extracts Technologies (CSE: PULL) Signs LOI with PURICA(TM) to Further Research into Mushrooms Wellness Products”
Pure Extracts is working with Dr. Alexander MacGregor on development of mushroom products, including some combined with CBD. MacGregor is widely renowned as pharmaceutical science inventor, expert in pharmaceutical technology and novel drug-delivery systems. Pure Extracts is focused on expansion of its cannabis extraction business model to include mushroom formulations. Pure Extracts Technologies (CSE: PULL) … Continue reading “Pure Extracts Technologies Corp. (CSE: PULL) Names Key Advisor; Targets Development of Mushroom Formulations”
